Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs Regeneron Pharmaceuticals Inc — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.19 (market cap $1.45B), while Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 52.5× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion NASDAQ 100 Equal Weighted Index Shares for 47 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| QQQE | REGN | |
|---|---|---|
Market Cap | $1.45B | $76.14B |
Volume | 323,568 | 500,239 |
Sector | Broad Market / Factor | Health |
52-Week High | $124.69 | $852.03 |
52-Week Low | $96.06 | $557.73 |
Typical Hold Time | 47 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE trades at $121.89, down 0.89% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF provides equal-weighted exposure to NASDAQ-100 large-cap growth stocks, reducing technology concentration compared to market-cap weighted alternatives. Recent analysis highlights QQQE's tactical appeal for diversification within tech-heavy indices.
The equal-weight methodology offers fundamental diversification benefits, though specific financial ratios are unavailable for the ETF structure. Market sentiment appears constructive with technical strength, but investors face typical ETF risks including market volatility and sector concentration despite the equal-weight approach.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
